RAD52 is a therapeutic vulnerability for acquired PARP inhibitor resistance in ovarian cancer.

Ota Y, Elizagaray ML, Gupta V, Fashemi BE, Akande M, Babu P, Thuthika PK, Lomonosova E, Brill J, Sun L, Sanders B, Kuroki LM, McCourt CK, Hagemann AR, Hagemann IS, Thaker PH, Mutch DG, Powell MA, Hyrc K, Verma P, Krais J, Bitler BG, Mullen MM, Khabele D

Open source

DOI: 10.1172/jci.insight.205126
Published: 2026 Nov 9
Container: JCI insight
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1172/jci.insight.205126,
  title = {RAD52 is a therapeutic vulnerability for acquired PARP inhibitor resistance in ovarian cancer.},
  author = {Ota Y and Elizagaray ML and Gupta V and Fashemi BE and Akande M and Babu P and Thuthika PK and Lomonosova E and Brill J and Sun L and Sanders B and Kuroki LM and McCourt CK and Hagemann AR and Hagemann IS and Thaker PH and Mutch DG and Powell MA and Hyrc K and Verma P and Krais J and Bitler BG and Mullen MM and Khabele D},
  year = {2026},
  journal = {JCI insight},
  doi = {10.1172/jci.insight.205126},
  url = {https://doi.org/10.1172/jci.insight.205126}
}

RIS

TY  - JOUR
TI  - RAD52 is a therapeutic vulnerability for acquired PARP inhibitor resistance in ovarian cancer.
AU  - Ota Y
AU  - Elizagaray ML
AU  - Gupta V
AU  - Fashemi BE
AU  - Akande M
AU  - Babu P
AU  - Thuthika PK
AU  - Lomonosova E
AU  - Brill J
AU  - Sun L
AU  - Sanders B
AU  - Kuroki LM
AU  - McCourt CK
AU  - Hagemann AR
AU  - Hagemann IS
AU  - Thaker PH
AU  - Mutch DG
AU  - Powell MA
AU  - Hyrc K
AU  - Verma P
AU  - Krais J
AU  - Bitler BG
AU  - Mullen MM
AU  - Khabele D
PY  - 2026
JO  - JCI insight
DO  - 10.1172/jci.insight.205126
UR  - https://doi.org/10.1172/jci.insight.205126
ER  -

APA

Y, O., ML, E., V, G., BE, F., M, A., P, B., PK, T., E, L., J, B., L, S., B, S., LM, K., CK, M., AR, H., IS, H., PH, T., DG, M., MA, P., K, H., P, V., J, K., BG, B., MM, M., & D, K. (2026). RAD52 is a therapeutic vulnerability for acquired PARP inhibitor resistance in ovarian cancer.. JCI insight. https://doi.org/10.1172/jci.insight.205126

Source records

pubmed · retrieved 2026-11-10T11:27:14.706Z